The Median Effective Dose of Remimazolam for Duodenoscopy Insertion During ERCP With Alfentanil 10µg/kg

• Status: Not yet recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Remimazolam has shown promising results for sedation in colonoscopy . Alfentanil is widely used in the analgesia of ERCP . The purpose of the study was to determine the median effective dose of remimazolam for duodenoscopy insertion during ERCP with alfentanil 10µg/kg.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tianjin Nankai Hospital

Criteria

Inclusion Criteria:

• Age is between 18 and 85 years

• ASA I and II levels;

• Patients undergone elective ERCP surgery, non-intubation patients;

Exclusion Criteria:

• Chronic pain with long-term use of analgesics, psychotropic substances (including opioids, NSAIDs, sedatives, antidepressants), alcohol abusers, with known drug allergy;

• 15 percent of body weight below or above standard weight;

• Abnormal liver or renal function (ALT#AST#BUN or Cr ) ; • Previous abnormal surgical anesthesia recovery history;

• Hypertension or systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 95 mmHg when the patient admission to the operating room

• Suffering from esophageal reflux; • Sedatives, analgesics and antipruritic drugs were used 24 hours before operation;

• Expected difficult intubation ; • Liver surgery history;

• Opioids allergy history;

• Take monoamine oxidase inhibitor or antidepressant within 15 days; • Shock;

• COPD;

• Pregnant or parturient women;

• Involved in other drug trials within three months;

• Patients who can not communicate well with the researcher